Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.51 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.49 |
| ▸ | CHRNG | P07510 | 1/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.49 |
| ▸ | CHRND | Q07001 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31556273 | 0.89 | GNPAT (0.60) | GNPATITGB3ITGA2BSLC15A2ERAP2 | |
| SCHEMBL1711945 | 0.89 | SLC15A2 (0.62) | GNPATITGB3ITGA2BSLC15A2ERAP2 | |
| SCHEMBL1711937 | 0.89 | SLC15A2 (0.62) | GNPATITGB3ITGA2BSLC15A2ERAP2 | |
| SCHEMBL30402874 | 0.89 | GNPAT (0.55) | GNPATITGB3ITGA2BSLC15A2ERAP2 | |
| SCHEMBL31181180 | 0.87 | ERAP2 (0.57) | GNPATERAP2LNPEPOPRK1 | |
| SCHEMBL30900769 | 0.85 | SLC15A2 (0.58) | GNPATITGB3ITGA2BSLC15A2ERAP2 | |
| SCHEMBL1711765 | 0.84 | GNPAT (0.63) | GNPATERAP2LNPEPECE1OPRK1 | |
| SCHEMBL3801759 | 0.84 | GNPAT (0.78) | GNPATITGB3ITGA2BERAP2LNPEP | |
| SCHEMBL1711598 | 0.84 | GNPAT (0.63) | GNPATERAP2LNPEPECE1OPRK1 | |
| SCHEMBL1711769 | 0.84 | GNPAT (0.63) | GNPATERAP2LNPEPECE1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | GNPAT 2493/4885ITGB3 4288/4885ITGA2B 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.